562 related articles for article (PubMed ID: 32679922)
41. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
42. Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers.
Bashir B; Flickinger JC; Snook AE
Immunotherapy; 2021 May; 13(7):561-564. PubMed ID: 33724866
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy of cancer.
Borghaei H; Smith MR; Campbell KS
Eur J Pharmacol; 2009 Dec; 625(1-3):41-54. PubMed ID: 19837059
[TBL] [Abstract][Full Text] [Related]
44. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
45. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
46. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy.
Gavali S; Liu J; Li X; Paolino M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639141
[TBL] [Abstract][Full Text] [Related]
47. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
48. Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.
Shebbo S; Binothman N; Darwaish M; Niaz HA; Abdulal RH; Borjac J; Hashem AM; Mahmoud AB
Front Immunol; 2024; 15():1350208. PubMed ID: 38533510
[TBL] [Abstract][Full Text] [Related]
49. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Ascierto PA; Brugarolas J; Buonaguro L; Butterfield LH; Carbone D; Daniele B; Ferris R; Fox BA; Galon J; Gridelli C; Kaufman HL; Klebanoff CA; Melero I; Nathan P; Paulos CM; Ruella M; Sullivan R; Zarour H; Puzanov I
J Immunother Cancer; 2018 Jul; 6(1):69. PubMed ID: 29996914
[TBL] [Abstract][Full Text] [Related]
50. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
51. Can immuno-oncology offer a truly pan-tumour approach to therapy?
Eggermont AM
Ann Oncol; 2012 Sep; 23 Suppl 8():viii53-7. PubMed ID: 22918930
[TBL] [Abstract][Full Text] [Related]
52. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Zamarin D; Jazaeri AA
Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
[TBL] [Abstract][Full Text] [Related]
53. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
54. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.
Patel RB; Baniel CC; Sriramaneni RN; Bradley K; Markovina S; Morris ZS
Brachytherapy; 2018; 17(6):995-1003. PubMed ID: 30078541
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH; Najjar YG
Nat Rev Immunol; 2024 Jun; 24(6):399-416. PubMed ID: 38057451
[TBL] [Abstract][Full Text] [Related]
56. Recent advances in immunotherapy in cancer treatment.
Patel AA
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):89-99. PubMed ID: 38814230
[TBL] [Abstract][Full Text] [Related]
57. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Mougel A; Terme M; Tanchot C
Front Immunol; 2019; 10():467. PubMed ID: 30923527
[TBL] [Abstract][Full Text] [Related]
59. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
60. Acquired and intrinsic resistance in cancer immunotherapy.
Kelderman S; Schumacher TN; Haanen JB
Mol Oncol; 2014 Sep; 8(6):1132-9. PubMed ID: 25106088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
